Safety and tolerability of FOLFOX4 in the adjuvant treatment of colon cancer in Asian patients: The MASCOT study

Asia-Pacific Journal of Clinical Oncology

Volumn 5, Issue 2, 2009, Pages 101-110

  Lee, Po Huang ^a   Park, Young Suk ^b   Ji, Jia Fu ^c   Fu, Yiu Tung ^d   Ratanatharathorn, Vorachai ^e  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b Samsung Medical Center   (South Korea)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^d QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^e MAHIDOL UNIVERSITY   (Thailand)

Author keywords

5 fluorouracil; Asia; Colorectal cancer; FOLFOX4; Leucovorin; MASCOT; Oxaliplatin; Safety; Tolerability

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADJUVANT THERAPY; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTICLE; ASIAN; BILIARY TRACT DISEASE; BLEEDING; BLOOD CLOTTING DISORDER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE DISORDER; FATIGUE; FEASIBILITY STUDY; FEVER; GASTROINTESTINAL DISEASE; HUMAN; ILEUS; INFECTION; INSOMNIA; LIVER DISEASE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 4 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISEASE; STOMACH CANCER; STOMATITIS; THROMBOCYTE; TOTAL COLON RESECTION; TREATMENT PLANNING; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

EID: 66949113989     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2009.01199.x     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J etal. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Sung JJY, Lau JYW, Goh KL etal. for the Asia Pacific Working Group on Colorectal Cancer. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005; 6: 871-6.
3. Chakraborty D, Fox-Tucker J. The Asian Cancer Market Outlook to 2010. Business Insights Ltd, 2005 [Cited 15 May 2009]Available at: http://www.globalbusinessinsights.com/content/rbhc0148t.pdf.
4. Diaz-Canton EA, Pazdur R. Adjuvant medical therapy for colorectal cancer. Surg Clin North Am 1997; 77: 211-28.
5. Abulafi AM, Williams NS. Local recurrence of colorectal cancer: The problems, mechanisms, management and adjuvant therapy. Br J Surg 1994; 81: 7-19.
6. Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11: 1879-87.
7. O'Connell MJ, Mailliard JA, Kahn MJ etal. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246-50.
8. Zaniboni A. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: Impact on disease-free survival and overall survival. J Clin Oncol 1997; 15: 2432-41.
9. O'Connell MJ, Laurie JA, Kahn M et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16: 295-300.
10. Porschen R, Bermann A, Löffler T et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: Results of the trial adjCCA-01. J Clin oncol 2001; 19: 1787-94.
11. Diaz-Rubio E, Sastre J, Zaniboni A etal. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Annals Oncol 1998; 9: 105-8.
12. Becouarn Y, Ychou M, Ducreux M et al. Oxaliplatin (L-OHP) as first line chemotherapy in metastatic colorectal cancer (MCRC) patients: preliminary activity/toxicity report. Proc Am Soc Clin Oncol 1997; 16: 229a [Abstract 804].
13. Simpson D, Dunn C, Curran M et al. Oxaliplatin: A review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs 2003; 63: 2127-56.
14. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
15. Colucci G, Gebbia V, Paoletti G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23: 4866-75.
16. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
17. Rothenberg ML, Oza AM, Bigelow RH etal. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-69.
18. Goldberg RM, Sargent DJ, Morton RF et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously unrelated metastatic colorectal cancer: A North American Intergroup Trial. J Clin Oncol 2006; 24: 3347-53.
19. AndréT, Boni C, Mounedji-Boudiaf L et al. for the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51.
20. de Gramont A, Boni C, Navarro M et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J Clin Oncol 2007; 25: 18s (Suppl) [Abstract 4007].
21. Hickish T, Boni C, Tabernero J et al. Oxaliplatin/5-fluorouracil/ leucovorin in stage II and III colon cancer: Updated results of the international randomized "MOSAIC" trial. Gastrointestinal Cancers Symposium 2004; [Abstract 211] [Cited 15 May 2009]. Available at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview= abst_detail_view&confID=27&abstractID=333.
22. Lim EH, Lim RSC, Wong JEL et al. Oxaliplatin (Ox)/5-fluorouracil (5FU)/ leucovorin (LV)-Folfox 4 is an effective chemotherapy combination for advanced colorectal carcinoma (CRC) in an Asian population. Proc Am Soc Clin Oncol 2001; 20: [Abstract 2205] [Cited 15 May 2009]. Available at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview= abst_detail_view&confID=10&abstractID=2205.
23. Lim EH, Lim RSC, Wu TS et al. Oxaliplatin/fluorouracil/leucovorin in advanced colorectal carcinoma: An Asian experience. Ann Pharmacother 2003; 37: 1909-12.
24. Yang T-S, Chen J-S, Tang R et al. Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: A phase II study. Chemother 2003; 49: 194-9.
25. Park SH, Sung JY, Han S-H et al. Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: A Korean single-center experience. Jpn J Clin Oncol 2005; 35: 531-5.
26. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-47.
27. Kemeny N, Garay CA, Gurtler J et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 2004; 22: 4753-61.
28. Hospers GAP, Schaapveld M, Nortier JWR et al. Randomised phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer. Ann Oncol 2006; 17: 443-9.
29. Kuebler JP, Wieand HS, O'Connell MJ et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 2007; 25: 1-7.
30. National Comprehensive Cancer Network (NCCN) guidelines for use of chemotherapy in patients with advanced colorectal cancer who are able to tolerate intensive therapy. Clinical practice guidelines in oncology: colon cancer. [Cited 15 May 2009]. Available at: https://subscriptions.nccn.org/login.aspx.
31. Benson AB III, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408-19.
32. Engstrom PF, Benson AB 3rd, Chen YJ et al. National Comprehensive Cancer Network: Colon cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2005; 3: 468-91.
33. Mamounas E, Wieand S, Wolmark N etal. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17: 1349-55.
34. International multicentre pooled analysis of B2 Colon cancer trials (IMPACT B2) investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999; 17: 1356-63.
35. Hickish T, Boni C, Navarro M et al. FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial. J Clin Oncol 2004; 22: [Abstract 3619]. [Cited 15 May 2009]. Available at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview= abst_detail_view&confID=26&abstractID=3572.
36. Cancer News Content. ASCO: Oxaliplatin therapy lengthens overall colon cancer survival. Originally published: June 4, 2007. [Cited 11 November 2008.]Available from: http://cancernews.mediwire.com/main/Default.aspx?P= Content&ArticleID=540443
37. Extra JM, Espie M, Calvo F et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299-303.
38. Nordlinger B, Rougier PH, Boudiaf L et al. Pre- and post-operative chemotherapy with oxaliplatin 5-FU/LV versus surgery alone in resectable liver metastases from colorectal origin - phase III study. [Cited 7 January 2008.] Available from: http://www.klinik.uni-frankfurt.de/alm/ info/download/PROTOCOL-40983.pdf
39. Ma C-J, Hsieh J-S, Chen F-M et al. Oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) in metastatic colorectal cancer (CRC). J Soc Colon Rectal Surgeon (Taiwan) 2007; 18: 65-70.
40. Keam B, Im S-A, Han S-W et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 2008; 8: 148.